Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection

The Original Article is available

Correction to: Clin Drug Investig (2018) 38:239–247 https://doi.org/10.1007/s40261-017-0606-0

The original version of this article unfortunately contained a mistake. The correct information is given below.

Page 242, Section 3.3, 1st paragraph, which previously read:

Baseline virologic resistance was assessed in all patients, except for one patient with HCV mono-infection who had other virologic outcome (n = 124). NS5A was successfully deep-sequenced in all 124 patients. At baseline, 2% (3/124) of patients had NS5A RASs using a 15% assay cut-off; one genotype 1b-infected patient had the L31M RAS, and two genotype 1b-infected patients had the Y93H RAS. NS5B was successfully deep-sequenced in 123 patients; NS5B amplification failed in one patient co-infected with genotype 1 HCV and HIV. Thirty-four genotype 1b-infected patients had L159F NS5B NI RAS present at baseline using a 15% assay cut-off. All patients with baseline RASs achieved SVR12. None of the patients who relapsed had any RASs at baseline or time of virologic failure.

Should read:

Baseline virologic resistance was assessed in all patients, except for one patient with HCV mono-infection who had other virologic outcome (n = 125). NS5A was successfully deep-sequenced in all 125 patients. At baseline, 3% (4/125) of patients had NS5A RASs using a 15% assay cut-off; one genotype 1b-infected patient had the L31M RAS, and three genotype 1b-infected patients had the Y93H RAS. NS5B was successfully deep-sequenced in 124 patients; NS5B amplification failed in one patient co-infected with genotype 1 HCV and HIV. Thirty-five genotype 1b-infected patients had L159F NS5B NI RAS present at baseline using a 15% assay cut-off. All patients with baseline RASs achieved SVR12. None of the patients who relapsed had any RASs at baseline or time of virologic failure.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vasily Isakov.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Isakov, V., Gankina, N., Morozov, V. et al. Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clin Drug Investig (2021). https://doi.org/10.1007/s40261-021-01014-9

Download citation